Introduction to Levodopa (L-dopa) Levodopa, chemically known as L-3,4-dihydroxyphenylalanine, or more commonly referred to as L-dopa, represents the most critical therapeutic agent in the management of Parkinson’s disease (PD) and related movement disorders characterized by dopamine depletion. PD is pathologically defined by the degeneration of dopaminergic neurons in the substantia nigra, leading to a profound […]
Pseudoparkinsonism: A Review Abstract Pseudoparkinsonism is a neurological disorder characterized by the presence of parkinsonian-like symptoms, such as bradykinesia, rigidity, and tremor, without any evidence of degeneration of the dopaminergic pathways in the brain. This disorder occurs as a result of various medications and medical conditions that interfere with normal central nervous system functioning. In […]
Bradykinesia: Understanding Slowness of Movement The Core Definition Bradykinesia is a fundamental motor disorder characterized by a distinct slowness of movement, a pronounced reduction in spontaneous or automatic movements, and a general decrease in overall physical activity. It represents more than just a simple slowing; it involves an impairment in the speed and amplitude of […]